Stiripentol
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Stiripentol |
| DrugBank ID | DB09118 |
| Brand Names (EU) | Diacomit |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 98.76% |
Approved Indication (EMA)
Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | restless legs syndrome | 98.76% | DL |
| 2 | trigeminal nerve neoplasm | 97.15% | DL |
| 3 | West syndrome | 94.97% | DL |
| 4 | developmental and epileptic encephalopathy | 94.55% | DL |
| 5 | 1q44 microdeletion syndrome | 94.31% | DL |
| 6 | episodic kinesigenic dyskinesia | 94.17% | DL |
| 7 | acute encephalopathy with biphasic seizures and late reduced diffusion | 94.14% | DL |
| 8 | PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation | 94.03% | DL |
| 9 | neonatal period electroclinical syndrome | 93.82% | DL |
| 10 | Wernicke-Korsakoff syndrome | 93.80% | DL |
| 11 | myoclonic epilepsy, Hartung type | 93.70% | DL |
| 12 | X-linked dominant intellectual disability-epilepsy syndrome | 93.56% | DL |
| 13 | insomnia (disease) | 93.45% | DL |
| 14 | DK1-CDG | 93.33% | DL |
| 15 | genetic lethal multiple congenital anomalies/dysmorphic syndrome | 93.30% | DL |
| 16 | infancy electroclinical syndrome | 93.30% | DL |
| 17 | microtriplication 11q24.1 | 93.09% | DL |
| 18 | sleep disorder, initiating and maintaining sleep | 93.02% | DL |
| 19 | guanidinoacetate methyltransferase deficiency | 92.91% | DL |
| 20 | CCDC115-CDG | 92.79% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.